By Product Type-
By Application Type-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Drug Infusion Systems Market Snapshot
Chapter 4. Global Drug Infusion Systems Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Dynamics - Drivers
4.3. Challenges/Restraints
4.4. Market Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2018 & 2028
5.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2018 to 2028 for the following Product Type:
5.2.1. Large Volume Infusion Systems
5.2.2. Patient Controlled Analgesia
5.2.3. Elastomeric Infusion Pumps
5.2.4. Insulin Infusion Pumps
5.2.5. Syringe Infusion Systems
5.2.6. Implantable Infusion Systems
5.2.7. Ambulatory Infusion Systems
5.2.8. Enteral Infusion Systems
Chapter 6. Drug Infusion Systems Market Segmentation 2: Application Estimates & Trend Analysis
6.1. Application Analysis & Market Share, 2019 & 2031
6.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
6.2.1. Oncology/Chemotherapy
6.2.2. Diabetes
6.2.3. Analgesia
6.2.4. Nutrition
6.2.5. Haematology
6.2.6. Paediatrics
6.2.7. Other Applications
Chapter 7. Drug Infusion Systems Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Product Type, 2019-2031
7.1.2. North America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Application, 2019-2031
7.1.3. North America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by country, 2019-2031
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Product Type, 2019-2031
7.2.2. Europe Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Application, 2019-2031
7.2.3. Europe Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) by country, 2019-2031
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Product Type, 2019-2031
7.3.2. Asia Pacific Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Application, 2019-2031
7.3.3. Asia Pacific Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) by country, 2019-2031
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Product Type, 2019-2031
7.4.2. Latin America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Application, 2019-2031
7.4.3. Latin America Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2019-2031
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Product Type, 2019-2031
7.5.2. MEA Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by Application, 2019-2031
7.5.3. MEA revenue Drug Infusion Systems Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2019-2031
7.5.3.1. South Africa
7.5.3.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Acromed AG
8.2.2. B. Braun Melsungen AG
8.2.3. Baxter International Inc.
8.2.4. Becton, Dickinson and Company
8.2.5. Caesarea Medical Electronics Ltd.
8.2.6. Debiotech S.A.
8.2.7. Flowonix Medical Inc.
8.2.8. Fresenius SE & Co. KGaA
8.2.9. Halyard Health, Inc.
8.2.10. ICU Medical Inc.
8.2.11. IRADIMED CORPORATION
8.2.12. Insulet Corporation
8.2.13. Medtronic Public Limited Company
8.2.14. MOOG, Inc.
8.2.15. Smiths Group plc
8.2.16. Tandem Diabetes Care, Inc.
8.2.17. Terumo Corporation
8.2.18. Zyno Medical, LLC
8.3. List of Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.